Comparison
Dulaglutide vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
923950-08-7
80714-61-0
Molecular weight
59670 g/mol
813.92 g/mol
Half-life
110 h
0.3 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcMet-Glu-His-Phe-Pro-Gly-ProMechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
5
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
1